HEMERION Therapeutics is a clinical-stage healthcare company focused on the discovery and development of innovative therapies that combine photosensitizing molecules and laser light technologies. This combination product strategy is aimed at the selective treatment of resistant tumors. More specifically, the company is positioned in oncology and has dedicated its first « best-in-class » drug-device combination program to target glioblastoma as its first indication. Hemerion’s technology is based on the unprecedented combination of a photosensitizing drug and an innovative photonic device.

The product combination integrates seamlessly into the surgical workflow and destroys tumor cells without harming healthy cells, leading to more favorable disease outcomes with longer progression-free survival (PFS) and overall survival (OS). With two successful clinical trials already completed in France, Hemerion is sponsoring a new clinical trial in the U.S. after receiving IND approval from the FDA during 2023. Having raised more than $16 million since the inception of the company, Hemerion is preparing their upcoming pivotal clinical trial towards a planned market approval in 2030.